Atle Fund Management AB
CIK 1381843 · View on SEC EDGAR ↗
- Portfolio value
- $371.7M
- Positions
- 39
- As of
- June 30, 2026
#4,548 of 9,443 by 13F value · top 48.2%
Portfolio value QoQ: +20.0% 13F does not disclose cash
- Top 10 holdings weight
- 48.00%
- Top 25 holdings weight
- 83.67%
- Positions above 1%
- 33
- Effective number of positions
- 26.6
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 28.96% Est. buys $98,661,342 · sells $289,214,085
Median holding: 5.0 quarters Tracked Q4 2024–Q2 2026 · 67.2% still held
- New positions
- 3
- Increased
- 16
- Decreased
- 20
- Closed
- 3
On this page
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
Sector breakdown
Healthcare
100.0%
Full portfolio 39 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company Common Stock | $35,768,202 | 9.62% | 29,821 | $8,922,876 | Down ×1 | ||
| MRK Merck & Company, Inc. Common Stock (new) | $24,332,374 | 6.55% | 189,357 | $1,415,205 | Up ×1 | ||
| JNJ Johnson & Johnson Common Stock | $21,695,387 | 5.84% | 85,425 | $9,752,294 | Down ×1 | ||
| ABBV AbbVie Inc. Common Stock | $16,186,743 | 4.35% | 64,325 | $5,800,944 | Down ×1 | ||
| CVS CVS Health Corporation Common Stock | $15,114,251 | 4.07% | 146,102 | $5,847,030 | Up ×1 | ||
| TMO Thermo Fisher Scientific Inc Common Stock | $13,967,388 | 3.76% | 27,859 | $-482,610 | Up ×1 | ||
| RVMD Revolution Medicines, Inc. - Common Stock | $13,685,860 | 3.68% | 73,077 | $4,608,837 | Down ×1 | ||
| BIIB Biogen Inc. - Common Stock | $13,564,462 | 3.65% | 62,781 | Up ×1 | |||
| NBIX Neurocrine Biosciences, Inc. - Common Stock | $12,285,864 | 3.31% | 72,898 | $4,431,394 | Down ×3 | ||
| MIRM Mirum Pharmaceuticals, Inc. - common stock | $11,801,475 | 3.17% | 100,807 | $2,403,935 | Down ×1 | ||
| ALKS Alkermes plc - Ordinary Shares | $11,177,372 | 3.01% | 213,329 | $2,941,852 | Down ×1 | ||
| IONS Ionis Pharmaceuticals, Inc. - Common Stock | $10,873,116 | 2.93% | 137,131 | $1,474,326 | Up ×1 | ||
| ONC BeOne Medicines Ltd. - American Depositary Shares | $10,025,244 | 2.70% | 35,180 | $-2,111,919 | Down ×1 | ||
| ISRG Intuitive Surgical, Inc. - Common Stock | $9,805,198 | 2.64% | 24,656 | $360,435 | Down ×1 | ||
| SYK Stryker Corporation Common Stock | $9,534,299 | 2.57% | 30,283 | $-45,413 | Up ×1 | ||
| VRTX Vertex Pharmaceuticals Incorporated - Common Stock | $9,502,941 | 2.56% | 19,131 | $-1,665,024 | Down ×1 | ||
| EW Edwards Lifesciences Corporation Common Stock | $9,338,185 | 2.51% | 103,230 | $1,071,527 | Down ×1 | ||
| BBIO BridgeBio Pharma, Inc. - Common Stock | $9,288,177 | 2.50% | 124,707 | $-2,605,304 | Up ×1 | ||
| KRYS Krystal Biotech, Inc. - Common Stock | $8,927,141 | 2.40% | 24,019 | $2,133,325 | Down ×1 | ||
| COR Cencora, Inc. Common Stock | $8,808,035 | 2.37% | 31,126 | $2,204,813 | Up ×1 | ||
| NAMS NewAmsterdam Pharma Company N.V. - Ordinary Shares | $8,433,458 | 2.27% | 248,848 | $2,925,178 | Up ×1 | ||
| ABVX Abivax SA - American Depositary Shares | $7,751,734 | 2.09% | 58,170 | $2,968,138 | Up ×1 | ||
| INCY Incyte Corporation - Common Stock | $6,456,192 | 1.74% | 56,953 | $-1,517,936 | Up ×1 | ||
| IRTC iRhythm Holdings, Inc. - Common Stock | $6,435,432 | 1.73% | 54,102 | $175,770 | Up ×1 | ||
| BSX Boston Scientific Corporation Common Stock | $6,247,541 | 1.68% | 146,381 | $-2,596,695 | Up ×1 | ||
| INSM Insmed Incorporated - Common Stock | $6,224,262 | 1.67% | 58,378 | $269,191 | Down ×1 | ||
| TNGX Tango Therapeutics, Inc. - Common Stock | $6,206,891 | 1.67% | 198,557 | $2,577,313 | Up ×1 | ||
| GILD Gilead Sciences, Inc. - Common Stock | $5,829,580 | 1.57% | 46,142 | $-1,326,930 | Down ×3 | ||
| CAH Cardinal Health, Inc. Common Stock | $5,613,542 | 1.51% | 23,630 | $845,332 | Down ×1 | ||
| ORKA Oruka Therapeutics, Inc. - Common Stock | $5,223,500 | 1.41% | 54,886 | Up ×1 | |||
| SYRE Spyre Therapeutics, Inc. - Common Stock | $5,063,123 | 1.36% | 57,030 | $1,577,316 | Down ×1 | ||
| DXCM DexCom, Inc. - Common Stock | $4,838,828 | 1.30% | 71,846 | $2,198,905 | Down ×1 | ||
| BCAX Bicara Therapeutics Inc. - Common Stock | $4,324,556 | 1.16% | 145,657 | $2,009,321 | Down ×1 | ||
| IDYA IDEAYA Biosciences, Inc. - Common Stock | $3,521,195 | 0.95% | 94,478 | $-490,299 | Up ×1 | ||
| CELC Celcuity Inc. - Common Stock | $3,485,206 | 0.94% | 33,313 | $-1,656,002 | Down ×1 | ||
| IRON Disc Medicine, Inc. - Common Stock | $3,194,901 | 0.86% | 43,682 | $6,214 | Down ×1 | ||
| PYXS Pyxis Oncology, Inc. - Common Stock | $2,909,041 | 0.78% | 966,459 | $1,290,988 | Up ×1 | ||
| CMPX Compass Therapeutics, Inc. - Common Stock | $2,296,418 | 0.62% | 1,048,593 | $-754,637 | Up ×1 | ||
| JBIO Jade Biosciences, Inc. - Common Stock | $1,967,714 | 0.53% | 88,556 | Up ×1 | |||
| No matches | |||||||
Biggest new bets
New positions opened this quarter, largest first.
Top movers (QoQ)
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| AMGN | June 30, 2026 | 21,903 | $8,716,028 | 20.5% |
| ITCI | March 31, 2025 | 71,138 | $5,938,600 | No longer tracked |
| UFPT | March 31, 2026 | 22,986 | $5,103,581 | 59.6% |
| VRNA | Sept. 30, 2025 | 47,100 | $4,454,718 | No longer tracked |
| FOLD | March 31, 2025 | 326,840 | $3,075,564 | No longer tracked |
| UNH | June 30, 2026 | 14,636 | $2,772,424 | -5.6% |
| ACLX | March 31, 2026 | 41,717 | $2,719,948 | No longer tracked |
| AUTL | March 31, 2026 | 1,169,634 | $2,327,571 | 79.0% |
| SLNO | June 30, 2026 | 90,184 | $2,207,336 | No longer tracked |
| CRBP | March 31, 2026 | 107,255 | $873,055 | 4.9% |
| MRSN | March 31, 2025 | 538,621 | $764,842 | No longer tracked |
| PHVS | March 31, 2025 | 34,328 | $652,919 | 132.6% |
| EW | Dec. 31, 2025 | 65,659 | $542,105 | 7.7% |
| MRUS | Dec. 31, 2025 | 47,999 | $479,766 | No longer tracked |
| HRMY | Dec. 31, 2025 | 92,074 | $269,397 | 5.5% |
| CABA | June 30, 2025 | 182,354 | $252,560 | 101.1% |
| RNA | Dec. 31, 2025 | 51,978 | $240,427 | -81.1% |
| SMMT | Dec. 31, 2025 | 92,737 | $203,404 | -28.1% |
| MREO | Dec. 31, 2025 | 764,901 | $167,282 | -26.3% |
| JANX | Dec. 31, 2025 | 49,820 | $129,265 | 26.1% |